Kyverna Therapeutics (NASDAQ:KYTX) Research Coverage Started at UBS Group

Investment analysts at UBS Group started coverage on shares of Kyverna Therapeutics (NASDAQ:KYTX) in a research note issued to investors on Thursday, Briefing.com reports. The firm set a “buy” rating and a $13.00 price target on the stock. UBS Group’s price target points to a potential upside of 188.25% from the stock’s current price.

KYTX has been the topic of a number of other reports. HC Wainwright restated a “neutral” rating and issued a $7.00 price target on shares of Kyverna Therapeutics in a research note on Thursday, September 19th. Rodman & Renshaw began coverage on shares of Kyverna Therapeutics in a research report on Wednesday. They issued a “buy” rating and a $16.00 target price on the stock. RODMAN&RENSHAW upgraded shares of Kyverna Therapeutics to a “strong-buy” rating in a report on Wednesday. Finally, JPMorgan Chase & Co. reduced their price objective on Kyverna Therapeutics from $39.00 to $33.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 31st. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $28.71.

Kyverna Therapeutics Price Performance

Shares of NASDAQ:KYTX opened at $4.51 on Thursday. Kyverna Therapeutics has a 1 year low of $4.42 and a 1 year high of $35.06. The company’s 50 day simple moving average is $6.76 and its 200 day simple moving average is $11.56.

Kyverna Therapeutics (NASDAQ:KYTX) last issued its earnings results on Monday, August 12th. The company reported ($0.67) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.70) by $0.03. Equities analysts anticipate that Kyverna Therapeutics will post -3.38 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. DekaBank Deutsche Girozentrale acquired a new stake in shares of Kyverna Therapeutics during the first quarter worth $181,000. Teachers Retirement System of The State of Kentucky grew its holdings in Kyverna Therapeutics by 69.7% during the 2nd quarter. Teachers Retirement System of The State of Kentucky now owns 21,410 shares of the company’s stock worth $161,000 after acquiring an additional 8,796 shares during the period. The Manufacturers Life Insurance Company raised its position in shares of Kyverna Therapeutics by 32.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 37,794 shares of the company’s stock worth $283,000 after acquiring an additional 9,300 shares in the last quarter. Skandinaviska Enskilda Banken AB publ lifted its stake in shares of Kyverna Therapeutics by 55.8% in the 2nd quarter. Skandinaviska Enskilda Banken AB publ now owns 26,195 shares of the company’s stock valued at $196,000 after purchasing an additional 9,385 shares during the period. Finally, Federated Hermes Inc. bought a new stake in shares of Kyverna Therapeutics during the 2nd quarter valued at about $120,000. Institutional investors and hedge funds own 18.08% of the company’s stock.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.